Closed tender

Compounded Infliximab for Intravenous Infusion

Details

Value
GBP 5,000,000
Topic
Pharmaceutical products
Published
3 August 2020
Submission
2 September 2020

Tender description

Provision of Compounded Infliximab to: Trusts who are members of: Thames Valley & Wessex Pharmacy Procurement Service NHS Commercial Solutions East of England NHS Collaborative Procurement Hub NHS London Procurement Partnership Full details of all Trusts involved can be found in the SSQ and ITT documents. These can be obtained from: https://www.nhssourcing.co.uk/bhft/web/login.shtml The requirement will be split into 5 Lots as follows: Lot 1 - Inflectra, Lot 2 - Remicade, Lot 3 - Remsima, Lot 4 - Flixabi, and Lot 5 - Zessly. This will be a ranked framework with a maximum of 5 suppliers per lot. The duration will be 2 years with 2 options for 12 month extensions (maximum duration 4 years).

Timeline

  1. Completed: Tender published3 August 2020
    Current notice
  2. Completed: Submission date2 September 2020

About the buyer

Berkshire Healthcare NHS Foundation Trust is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

  • 33600000 · Pharmaceutical products

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

6 similar open tenders

See more open tenders related to Compounded Infliximab for Intravenous Infusion.

Explore all open tenders

Win more public sector contracts

Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.